| Literature DB >> 35486371 |
Barry Schechter1, Francis Mah2.
Abstract
Ocular surface disease commonly exists in individuals requiring ophthalmic surgery and may compromise the structure and function of ocular surface components. Ophthalmic surgery may further affect the ocular surface by injuring the epithelium and sensory nerves, disrupting the tear film, or causing local inflammation. Medical management of ocular surface disease prior to ophthalmic surgery aids in reducing inflammation, resolving infection, improving epithelial pathology, stabilizing the tear film, and easing patient symptoms, promoting positive long-term outcomes and minimizing the incidence of postoperative complications. This review summarizes frequently encountered ocular surface diseases and available preoperative medical management options, discusses common ophthalmic surgeries and their effects on the ocular surface, examines potential postoperative complications, and defines recommendations for postoperative ocular surface maintenance.Entities:
Keywords: Cataract surgery; Dry eye disease; Ocular surface disease; Ocular surface optimization; Ophthalmic surgery; Refractive surgery
Year: 2022 PMID: 35486371 PMCID: PMC9114189 DOI: 10.1007/s40123-022-00505-y
Source DB: PubMed Journal: Ophthalmol Ther
Summary of medical management options
| Use(s) | Function | Mechanism of action | Contraindications or drawbacks | |
|---|---|---|---|---|
| Topical products | ||||
| Ocular lubricants | Allergic conjunctivitis, DED, epithelial basement membrane dystrophy, SND | Improvement of tear quantity and/or quality [ Relief of ocular discomfort [ | Ocular lubrication [ Supplementation or substitution of tear film components [ | Often inadequate for long-term management [ |
| Antihistamines | Allergic conjunctivitis | Ocular allergy symptom relief [ | H1 receptor antagonists | None |
| Antibiotics | Blepharitis | Treatment of infections | Bactericidal or bacteriostatic action | Risk of resistance with chronic or repeated use [ |
| Azithromycin | Blepharitis, MGD | Reduction of inflammation [ Improvement of meibomian gland function [ | Bacteriostatic action [ Inhibition of multiple inflammatory mediators [ Bacterial lipase inhibition [ | |
| Anti-inflammatories | ||||
| Non-steroidal anti-inflammatories | Allergic conjunctivitis | Reduction of inflammation | Cyclooxygenase inhibition | Risk of corneal toxicity with epithelial compromise [ |
| Corticosteroids | Allergic conjunctivitis, blepharitis, DED, MGD | Reduction of inflammation | Inhibition of multiple inflammatory mediators | Risk of cataracts or elevated IOP with long-term use [ |
| Immunomodulators | ||||
| Cyclosporine A | Allergic conjunctivitis, blepharitis, DED, MGD | Reduction of inflammation [ | Calcineurin inhibition [ | Long-term therapy required [ |
| Cyclosporine ophthalmic solution (Cequa™, Sun Pharmaceutical Industries, Inc.) | DED | Increase in tear production [ | ||
| Cyclosporine ophthalmic emulsion (Restasis®, Allergan, Inc.) | DED | Increase in tear production [ | ||
| Lifitegrast 5% ophthalmic solution (Xiidra®, Novartis Pharmaceuticals Corporation) | DED | Treatment of DED signs and symptoms [ | LFA-1 antagonist [ | None |
| Systemic products | ||||
| Omega-3 fatty acids | Blepharitis, DED, MGD | Reduction of inflammation [ | Inhibition of proinflammatory mediators [ | Debated efficacy [ |
| Oral antibiotics | ||||
| Macrolides | Blepharitis, MGD | Treatment of infection Reduction of inflammation [ | Bacteriostatic and/or bactericidal action Inhibition of multiple inflammatory mediators [ | Long-term use may cause resistance [ Oral azithromycin may cause abnormal cardiac electrical activity [ |
| Tetracyclines | Blepharitis, DED, MGD | Treatment of infection Reduction of inflammation [ Tear film stabilization [ | Bacteriostatic action Inhibition of multiple inflammatory mediators [ Bacterial lipase inhibition [ | Long-term use may cause resistance [ Contraindicated during pregnancy and in young children [ Risk of photosensitization, GI upset, vaginitis [ |
| Procedural therapies | ||||
| Meibomian gland thermal pulsation and expression | Blepharitis, MGD | Meibomian gland expression [ Improvement of meibomian gland function [ Relief of MGD symptoms [ | Application of heat to inner eyelid and pulsating pressure to outer eyelid [ | None |
| Punctal occlusion | DED | Tear film stabilization | Obstruction of punctal orifices for reduction of tear drainage [ | Controversial with active ocular surface inflammation [ Risks include epiphora, local irritation, infection [ |
| Intense pulsed light | Blepharitis, DED, MGD | Reduction of eyelid inflammation and telangiectasia [ | Mechanism of action unclear; use of light source with photothermal effect [ | Must be repeated for lasting effects [ |
| MBE | Blepharitis, | Removal of eyelid margin debris [ Resolution of meibomian gland obstruction [ | Mechanical debridement and exfoliation of eyelid margin [ | None |
| Other | ||||
| Lifestyle changes | ||||
| Regular screen breaks | DED | Tear film stabilization | Promotion of normal blinking to prevent abnormal tear film evaporation [ | None |
| Blinking exercises | DED | Tear film stabilization | Prevention of abnormal tear film evaporation [ | None |
| Avoidance of desiccating conditions | DED | Tear film stabilization | Prevention of abnormal tear film evaporation [ | None |
| Avoidance of allergen or irritant exposure | Allergic conjunctivitis | Reduction of ocular irritation | Prevention of exposure to irritating substances [ | None |
| Eyelid cleansing | Allergic conjunctivitis, blepharitis, DED, | Improvement of eyelid health Reduction of allergens or irritants | Mechanical removal of eyelid margin debris [ | Risk of injury if performed incorrectly [ |
| Tea tree oil cleansers | Reduction or elimination of | Oxygenated terpenoids with acaricidal action [ | Risk of ocular irritation [ | |
| Hypochlorous acid 0.01% cleansers | Blepharitis, MGD | Reduction of eyelid margin bacterial counts [ | Bactericidal action [ | Multiple daily treatments required for optimal effect [ |
| Warm compress and eyelid massage | Blepharitis, MGD, SND | Facilitation of meibomian gland expression [ Reduction of eyelid margin debris [ | Softening of debris facilitates mechanical removal [ Warming facilitates meibomian gland expression [ | Risk of injury if performed incorrectly [ Risk of elevated IOP in glaucoma patients [ |
DED dry eye disease, GI gastrointestinal, H1 histamine-1, IOP intraocular pressure, LFA-1 lymphocyte function-associated antigen-1, MBE microblepharoexfoliation, MGD meibomian gland dysfunction, SND Salzmann’s nodular degeneration
Preoperative patient assessments
| Preoperative assessment | Concept being evaluated |
|---|---|
| Patient history | Ocular disease signs or symptoms [ |
| Clinical examination | Ocular morphology [ Ocular disease signs [ |
| Slit-lamp biomicroscopy | Ocular morphology [ Meibomian gland expressibility: meibum quality and volume [ Tear film lipid layer, thickness, spread time and rate [ |
| Tear evaluation | |
| Osmolarity test | Tear osmolarity [ |
| Tear breakup time | Tear film stability: time between blink and break in tear film [ |
| Meniscus height | Tear volume [ |
| Schirmer test | Tear secretion over 5 min [ |
| Ocular surface staining | Integrity of conjunctival and corneal epithelium [ |
| Tonometry | Intraocular pressure [ |
| Fundoscopic exam | Ocular fundus (retina, macula, optic nerve) morphology [ |
| Visual acuity test | Accuracy of distance vision [ |
| Visual field test | Extent of peripheral vision [ |
| Biometry | Corneal refractive power [ Eye length [ |
| Corneal topography/keratometry | Anterior corneal surface curvature [ |
| Corneal tomography | Corneal thickness and shape [ |
Postoperative complications
| Complication | Etiology/risk factors |
|---|---|
Infection Infectious keratitis Endophthalmitis | Blepharitis [ DED [ |
| Foreign body sensation | Transection of corneal afferent sensory nerve fibers [ Postoperative changes to tear film and ocular surface epithelium causing chronic ocular irritation [ |
Visual changes Vision fluctuations Light scattering Glare effect Decreased visual acuity | Corneal structural abnormalities [ Corneal opacities [ Tear film instability [ |
Refractive errors Myopia Hyperopia Astigmatism Refractive regression | Corneal surface irregularity [ Large surgical incisions [ Biometry miscalculation [ Lens misalignment [ Prior laser refractive surgery [ DED [ |
Emergence or exacerbation of ocular surface diseases DED MGD | Incisional damage to corneal afferent sensory nerves [ Increased postoperative inflammatory mediators [ Tear film instability [ Preservative toxicity from medicated eye drops [ |
DED dry eye disease, MGD meibomian gland dysfunction
| Individuals requiring ophthalmic surgery commonly have pre-existing ocular surface diseases due to age or chronic use of topical ophthalmic medications, which may compromise the structure and function of ocular surface components. |
| Ophthalmic surgeries may further compromise the ocular surface by injuring the ocular epithelium and nerves, disrupting the tear film, and inducing inflammation. |
| Prior to ophthalmic surgery, appropriate medical management should be instituted for extant ocular surface diseases to reduce inflammation, treat infection, improve epithelial lesions, and stabilize the tear film. |
| Preoperative ocular surface optimization promotes positive surgical outcomes, improves patient satisfaction, and minimizes postoperative complications. |